checkAd
    Protagonist Therapeutics Aktie
    26,09
     
    USD
    +2,15 %
    +0,55 USD
    Letzter Kurs 04.05.24 Nasdaq
    26,04
     
    USD
    100 STK
    Geldkurs 03.05.24
    26,07
     
    USD
    300 STK
    Briefkurs 03.05.24
    ISIN: US74366E1029 · WKN: A2AP32 · SYM: PTGX · USA

    Neueste Nachrichten

    Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
    26.03.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
    18.03.24 · Accesswire · Protagonist Therapeutics
    Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
    11.03.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics to Participate in Upcoming Investor Conferences
    06.03.24 · Accesswire · Protagonist Therapeutics
    Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    27.02.24 · Accesswire · Protagonist Therapeutics
    New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
    21.02.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Reports Granting of Inducement Awards
    20.02.24 · Accesswire · Protagonist Therapeutics
    Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
    13.12.23 · Accesswire · Protagonist Therapeutics
    Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
    12.12.23 · Accesswire · Protagonist Therapeutics
    Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
    12.12.23 · Accesswire · Protagonist Therapeutics
    Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
    27.11.23 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Reports Granting of Inducement Awards
    16.11.23 · Accesswire · Protagonist Therapeutics